AstraZeneca reported May 14, 2026 that Imfinzi+chemo reduced death risk by 28% (HR 0.72) with median OS 22.4 vs 16.7 months, per Seeking Alpha and company release.
STAAR aims for ~75% gross margin and $225M capex in 2026; Switzerland to supply 100% of China lenses per Seeking Alpha (May 14, 2026).
Altimmune targets PERFORMA Phase III MASH start in 2H 2026 with a 52-week readout and reports cash runway to 2029 (Seeking Alpha, May 14, 2026).
Omeros projects company-wide positive cash flow within 18 months (May 14, 2026); Fazen Markets notes this is faster than the 30-month median for similar biotech launches.
Fangzhou and Tenry announced a diabetes partnership on May 14, 2026; 537m adults had diabetes in 2021 and global direct costs were $966bn (IDF).
Shoulder Innovations raised 2026 net revenue guidance to $65–68M on May 14, 2026; midpoint $66.5M implies ~$16.6M per quarter and signals stronger Q1 execution.
Myomo beat Q1 2026 estimates but shares fell 9.3% on May 14, 2026 after the earnings call (Investing.com); investors seek clarity on growth cadence and cash runway.
Precigen targets cash-flow breakeven by end-2026 (May 14, 2026); implies ~7.5 months to achieve breakeven after PAPZIMEOS launch, raising scrutiny on H2 2026 revenue and margins.
Adar1 Capital manager Daniel Schneeberger bought $711,054 of Rallybio stock, reported May 14, 2026; institutional investors should verify SEC filings and liquidity before acting.
enGene filed a Schedule 13G on May 13, 2026; SEC rules set a 5% reportable threshold and 45-/10-day reporting windows, prompting liquidity and governance checks.
Position yourself for the macro moves discussed above
Start TradingInovio sets INO‑3107 PDUFA for Oct 30, 2026 and reports cash runway into Q1 2027, covering operations through at least March 31, 2027 (Seeking Alpha, May 14, 2026).
Aytu sets $6M-$7M quarterly S&M budget and reports EXXUA prescriptions topped 920 in April 2026 (Seeking Alpha, May 14, 2026), signaling a critical commercialization test.
Showing 12 of 33
